利用基质锚定细胞因子增强ADCC:F16IL2联合BI 836858治疗移植后AML复发的1期试验
这项新型联合、剂量递增1期试验纳入移植后急性髓系白血病复发患者,评估F16IL2联合抗CD33抗体BI 836858的安全性、药代动力学、药效动力学和初步活性。15例患者中常见不良事件为发热、寒战和输注相关反应,多为≤2级;DL3和DL4各出现1例剂量限制性毒性。较高两个剂量组7例中观察到3例客观缓解,起始两个剂量组无缓解。
要点
- F16IL2联合BI 836858在移植后AML复发患者中安全性可接受,常见不良事件为发热、寒战和输注相关反应。
- DL3发生肺水肿、DL4发生移植物抗宿主病各1例剂量限制性毒性。
- 较高两个剂量组7例中3例客观缓解,起始两个剂量组无缓解。
核心结论
- 基质锚定IL-2联合抗CD33免疫治疗在移植后AML复发中安全性可接受,并显示出令人鼓舞的生物学和临床活性。
研究设计与样本
- 新型联合、剂量递增1期试验,纳入移植后急性髓系白血病复发患者,评估F16IL2联合BI 836858的安全性、药代动力学、药效动力学和初步活性。
- 共15例患者接受治疗,中位(范围)年龄50(20-68)岁,跨4个剂量水平。
- F16IL2剂量为10×10^6至20×10^6 IU静脉给药,每28天周期的第1、8、15、22天;BI 836858为10-40 mg静脉给药,每次F16IL2输注后2天。
- 试验在EudraCT注册,注册号为2015-004763-37。
主要发现
- 15例患者中6例(40%)曾接受2或3次既往移植。
- 最常见不良事件为发热、寒战和输注相关反应,可管理、短暂且≤2级。
- DL3发生1例剂量限制性毒性(肺水肿),DL4发生1例剂量限制性毒性(移植物抗宿主病)。
- 较高两个剂量组7例患者中观察到3例客观缓解,起始两个剂量组无缓解。
- 联合治疗刺激NK细胞扩增和活化,包括表达FcγRIIIA/CD16受体的NK细胞。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Natural killer (NK) cells are key effectors in cancer immunosurveillance and posttransplant immunity, but deficiency of environmental signals and insufficient tumor recognition may limit their activity. We hypothesized that the antibody-mediated anchoring of interleukin-2 (IL-2) to a spliced isoform of the extracellular matrix (ECM) glycoprotein tenascin-C would potentiate NK-cell-mediated antibody-dependent cellular cytotoxicity against leukemic blasts. In this novel-novel combination, dose-escalation, phase 1 trial, we enrolled patients with posttransplant acute myeloid leukemia (AML) relapse to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary activity of the antibody-cytokine fusion F16IL2 (10 × 106 to 20 × 106 IU IV; days 1, 8, 15, and 22 of each 28-day cycle) in combination with the anti-CD33 antibody BI 836858 (10-40 mg IV, 2 days after each F16IL2 infusion). Among the 15 patients (median [range] age, 50 [20-68] years) treated across 4 dose levels (DLs), 6 (40%) had received 2 or 3 prior transplantations. The most frequent adverse events were pyrexia, chills, and infusion-related reactions, which were manageable, transient and of grade ≤2. One dose-limiting toxicity occurred at each of DLs 3 (pulmonary edema) and 4 (graft-versus-host disease). Three objective responses were observed among 7 patients treated at the 2 higher DLs, whereas no responses occurred at the 2 starting DLs. Combination therapy stimulated the expansion and activation of NK cells, including those expressing the FcγRIIIA/CD16 receptor. ECM-targeted IL-2 combined with anti-CD33 immunotherapy represents an innovative approach associated with acceptable safety and encouraging biologic and clinical activity in posttransplant AML relapse. This trial was registered at EudraCT as 2015-004763-37.
引用
- Berdel AF, Ruhnke L, Angenendt L, et al. Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse. Blood Adv. 2022. PMID: 35468621. doi:10.1182/bloodadvances.2021006909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。